{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:45:02Z","timestamp":1786985102219,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.berh.2023.101842","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T10:52:47Z","timestamp":1688640767000},"page":"101842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in the maintenance of ANCA vasculitis remission"],"prefix":"10.1016","volume":"37","author":[{"given":"Lo\u00efc","family":"Guillevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2023.101842_bib2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"19","key":"10.1016\/j.berh.2023.101842_bib3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2023.101842_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lpm.2020.104034","article-title":"Treatment of systemic necrotizing vasculitides: the 40-year experience of the French Vasculitis Study Group","volume":"49","author":"Guillevin","year":"2020","journal-title":"Presse Med"},{"issue":"8","key":"10.1016\/j.berh.2023.101842_bib6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101842_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.berh.2023.101842_bib9","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.berh.2023.101842_bib10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101842_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.berh.2023.101842_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2023.101842_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2023.101842_bib15","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of corticosteroid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.berh.2023.101842_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.berh.2023.101842_bib17","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose versus high-dose corticosteroids added to rituximab on remission induction in ANCA-associated vasculitis","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infectioun prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2023.101842_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic antibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2023.101842_bib20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2215\/CJN.00100114","article-title":"Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis","volume":"9","author":"Walsh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.berh.2023.101842_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/keu429","article-title":"Indications for IVIG in rheumatic diseases","volume":"54","author":"Mulhearn","year":"2015","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2023.101842_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40265-018-0920-8","article-title":"Treatment of eosinophilic granulomatosis with polyangiitis. A review","volume":"78","author":"Raffray","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.berh.2023.101842_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.08-2990","article-title":"Churg\u2013Strauss syndrome in patients treated with omalizumab","volume":"136","author":"Wechsler","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.berh.2023.101842_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2023.101842_bib25","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2023.101842_bib26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101842_bib27","series-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial","author":"Terrier","year":"2021"},{"issue":"20","key":"10.1016\/j.berh.2023.101842_bib28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2023.101842_bib29","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.berh.2023.101842_bib30","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2023.101842_bib31","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology"},{"issue":"S3","key":"10.1016\/j.berh.2023.101842_bib32","article-title":"Pneumocystis jiroveci pneumonia following rituximab","volume":"60","author":"Rutter","year":"2021","journal-title":"Rheumatology"},{"issue":"Suppl 70","key":"10.1016\/j.berh.2023.101842_bib33","first-page":"S83","article-title":"Immunogenicity and safety of seasonal and 2009 pandemic A\/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients","volume":"30","author":"Kostianovsky","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101842_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02714432","article-title":"Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases","volume":"165","author":"Guillevin","year":"1987","journal-title":"Lung"},{"key":"10.1016\/j.berh.2023.101842_bib35","series-title":"Innovative anti-pneumococcal vaccine strategies versus standard vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: a multicenter randomized controlled trial (PNEUMOVAS). ACR Meeting Philadelphia, Abstracts","volume":"L16","author":"Terrier","year":"2022"},{"issue":"6","key":"10.1016\/j.berh.2023.101842_bib36","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101842_bib37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2023.101842_bib38","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1016\/S2665-9913(21)00316-7","article-title":"Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study","volume":"3","author":"Sattui","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"23","key":"10.1016\/j.berh.2023.101842_bib39","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101842_bib40","article-title":"Association between AZD7442 (tixagevimab\u2013cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality","volume":"29","author":"Kertes","year":"2022","journal-title":"Clin Infect Dis Published online July"},{"key":"10.1016\/j.berh.2023.101842_bib41","doi-asserted-by":"crossref","first-page":"o2690","DOI":"10.1136\/bmj.o2690","article-title":"Covid-19: evusheld protects the most vulnerable patients, analysis shows","volume":"379","author":"Iacobucci","year":"2022","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.berh.2023.101842_bib42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2023.101842_bib43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:25:16Z","timestamp":1761499516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521694223000281"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101842","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the maintenance of ANCA vasculitis remission","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101842"}}